Global Sustained Release Drugs Market, By Route of Administration (Oral, Intramuscular, Subcutaneous, Transdermal, Intravenous, Others), Mode (Over-the-Counter, Prescription), Distribution Channel (Hospital Pharmacies, Online Pharmacies), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights : Global Sustained Release Drugs Market
The sustained release drugs market is expected to gain growth at a potential rate of 8.00% in the forecast period of 2021 to 2028. The rise in research and development on novel drug delivery is the factor responsible for the market growth.
The sustained release drugs usually offer various advantages over conventional ones. These consist of better patient compliance, reduced incidence of side effects, low dosing frequency and overall cost reduction of medical care.
The rapid increase in the demand for pediatric and geriatric sustained release dosage forms is expected to accelerate the market growth in the forecast period of 2021 to 2028. Likewise, the sustained release drugs have been extensively accepted compared to immediate release formulations of the same drug which is also predictable to enhance the sustained release drugs market growth. Furthermore, the rise in government funding and rise in the awareness among people regarding benefits of sustained release are also projected to drive the market growth rate.
In addition, the continuous investment in R&D, presence of advanced research facilities and presence of leading pharmaceutical and biopharmaceutical companies are likely to create various new opportunities that will impact this sustained release drugs market growth in the forecast period of 2021 to 2028.
However, the dose dumping and high cost of the drug are expected to act as major restraints towards the growth of the sustained release drugs market, whereas limited amount of dosage is acceptable in pediatric conditions can challenge the growth of the target market in the above mentioned forecast period.
This sustained release drugs market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis on the sustained release drugs market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Sustained Release Drugs Market Scope and Market Size
The sustained release drugs market is segmented on the basis of route of administration, mode and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- The route of administration segment of the sustained release drugs market can be segmented into oral, intramuscular, subcutaneous, transdermal, intravenous and others.
- Based on mode, the sustained release drugs market can be segmented into over-the-counter and prescription.
- Based on distribution channel, the sustained release drugs market can be segmented into hospital pharmacies and online pharmacies.
Sustained Release Drugs Market Country Level Analysis
The sustained release drugs market is analyzed and market size information is provided by country by route of administration, mode and distribution channel as referenced above.
The countries covered in the sustained release drugs market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America leads the sustained release drugs market due to continuous investment in R&D and availability of highly sophisticated technologies. Asia-Pacific region is expected to expand at a significant growth rate in the forecast period of 2021 to 2028 because of the rapid development in the health care infrastructure and constant investment by companies in lower and middle income countries.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The sustained release drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Sustained Release Drugs Market Share Analysis
The sustained release drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to sustained release drugs market.
The major players covered in the sustained release drugs market report are Alkermes, Johnson & Johnson Services, Inc, Pfizer Inc, Dr. Reddy’s Laboratories Ltd., Boston Scientific Corporation, Baxter, Abbott, GlaxoSmithKline plc, Novartis AG, Sanofi, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., AstraZeneca, Allergan, Ipsen Pharma, Endo International plc, Janssen Pharmaceuticals, Inc., Eli Lilly and Company, Genentech, Inc., and Lonza among other domestic and global players. Sustained release drugs market share data is available for global, North America, South America, Europe, Asia-Pacific (APAC) and Middle East and Africa (MEA) separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-